ArticleFrontiers in immunology2026
Possible underdiagnosis of ulcerative colitis in tertiary care can affect medication use and access to healthcare facilities.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease where diagnostic delays can worsen the clinical outcomes and increase the strain on healthcare systems. This study investigated the frequency of potentially missed UC diagnoses in tertiary care and their impact on treatment patterns and healthcare utilization. Methods: We conducted a retrospective cohort study using Tuscany's regional healthcare database (2006-2020). Adults newly diagnosed with UC between 2011 and 2018 were included. A "possible missed diagnosis" was defined as a hospital or emergency department (ED) visit for gastrointestinal (GI) symptoms occurring 7-60 months before the UC diagnosis. We assessed the initiation of azathioprine and non-conventional therapies, as well as the rates of ED visits, hospital admissions, and surgery. Survival analyses and Cox regression models were applied. Results: Among 3,804 patients with UC, 313 (8.3%) had prior GI-related tertiary care visits suggestive of a missed diagnosis. The mean time to diagnosis was 27.5 months. Compared with those who were timely diagnosed, these patients were not more likely to start azathioprine or non-conventional therapies. However, subjects with a possible missed diagnosis had higher rates of ED visits [adjusted hazard ratio (aHR) = 1.8, 95%CI = 1.5-2.0], hospitalizations (aHR = 1.4, 95%CI = 1.2-1.7), and combined urgent care encounters (aHR = 1.5, 95%CI = 1.3-1.7) compared with other patients. Conclusions: Patients with a potentially missed UC diagnosis are more likely to need emergency and inpatient care, despite receiving similar treatments. Promoting earlier recognition of UC symptoms in tertiary care may reduce avoidable hospital use and improve disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.